면역글로불린 시장 규모, 점유율, 성장 및 세계 업계 분석 : 유형 및 용도별, 지역별 인사이트 및 예측(2026-2034년)

Growth Factors of immunoglobulin Market

The global immunoglobulin market was valued at USD 22.15 billion in 2025 and is projected to grow to USD 24.44 billion in 2026, eventually reaching USD 43.68 billion by 2034, exhibiting a CAGR of 7.53% during the forecast period. North America dominated the market in 2025, holding a 49.39% share, driven by the rising prevalence of immunodeficiency diseases, strong healthcare infrastructure, and innovative product launches.

Immunoglobulins, derived from human plasma, are critical therapies for immunodeficiency disorders, autoimmune conditions, and other chronic immune-mediated diseases. Their growing use as first-line treatments and the ongoing R&D investment by leading pharmaceutical companies such as CSL (Australia), Takeda Pharmaceutical Company Limited (Japan), Grifols, S.A. (Spain), and Octapharma AG (Switzerland) are key factors driving market expansion. Regulatory support and expedited approvals for new immunoglobulin products further strengthen the market growth trajectory.

Market Trends

A prominent global trend is the shift toward subcutaneous administration (SCIG). SCIG provides multiple advantages over intravenous administration (IVIG), including easier administration, improved safety, and the ability for patients to self-administer at home. This trend supports higher patient adherence and broader adoption. For instance, in June 2023, Grifols, S.A. launched XEMBIFY, a 20% SCIG product in Spain to boost accessibility and growth.

Market Drivers

The rising demand for treatment of immunodeficiency diseases such as Primary Immunodeficiency (PI), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Guillain-Barre Syndrome, and Multifocal Motor Neuropathy (MMN) drives immunoglobulin market growth. The increasing prevalence of these conditions expands the patient population and, consequently, the demand for immunoglobulin therapies. According to a February 2025 report by the U.S. Pharmacist, approximately 1-2% of the U.S. population is affected by primary immunodeficiency disorders (PIDDs).

Market Restraints

Stringent government regulations act as a significant restraint. Immunoglobulins are plasma-derived and must meet strict safety, potency, and quality standards. Regulatory bodies such as the U.S. FDA monitor plasma collection, processing, and distribution under the Public Health Service (PHS) Act and Federal Food, Drug, and Cosmetic (FD&C) Act. These requirements can limit rapid market expansion and increase production costs.

Market Opportunities

Expanding manufacturing capacity presents a major growth opportunity. Plasma availability and production constraints often create supply chain challenges. Companies are investing in higher-throughput purification systems, expanded fractionation lines, and improved packaging to meet rising demand. In February 2025, Octapharma AG expanded its Vienna manufacturing facilities to increase production of human plasma-based medicines.

Market Challenges

The high cost of immunoglobulin therapies poses a critical challenge. IVIG and SCIG therapies are expensive, with high out-of-pocket costs and variable reimbursement policies. Supply shortages also contribute to higher prices, restricting adoption. For example, a 2024 study on Myasthenia Gravis patients in Norway showed that IVIG treatment resulted in 2.3 times higher direct medical costs in the first year compared to untreated patients.

Market Segmentation

By Product Type:

• IVIG dominates the market due to hospital use and rapid onset of action for severe neuro-immunology conditions.
• SCIG is expected to grow at a CAGR of 11.18%, driven by self-administration convenience and patient preference.

By Form:

• Liquid immunoglobulin dominates in 2025, offering ready-to-use formulations that reduce contamination risk and preparation time.
• Lyophilized form is projected to grow at a CAGR of 2.97% during the forecast period.

By End User:

• Hospitals hold the largest share due to established infrastructure, patient monitoring, and reimbursement pathways.
• Home care is projected to grow at a CAGR of 9.18%, reflecting the rising adoption of SCIG therapies.

Regional Outlook

North America led the market with USD 11.46 billion in 2025, projected to reach USD 12.47 billion in 2026. The U.S. market alone is expected at USD 11.19 billion in 2026.

Europe generated USD 3.63 billion in 2025, reaching USD 3.91 billion in 2026, driven by government support and infrastructure development. Germany and the U.K. markets are estimated at USD 1.24 billion and USD 1.04 billion, respectively, in 2026.

Asia Pacific accounted for USD 3.38 billion in 2025, projected to reach USD 3.71 billion in 2026, with Japan and China leading at USD 1.41 billion and USD 2.12 billion, respectively. India is expected at USD 0.68 billion in 2026.

Latin America and Middle East & Africa are projected to grow moderately, with market sizes of USD 0.45 billion and USD 0.18 billion, respectively, in 2026. The GCC region alone is expected to reach USD 0.30 billion.

Competitive Landscape

The market is highly consolidated with key players including CSL, Takeda, Grifols, Kedrion, Octapharma, ADMA Biologics, Taibang Biologic, LFB Group, Shanghai RAAS Blood Products, and GC Biopharma. Strategic partnerships, new product launches, and regulatory approvals are core strategies driving their market positions. Notable developments include Takeda's Orphan Drug Designation for mezagitamab in June 2025 and Grifols' IND submission for GRF312 in May 2025.

Conclusion

The global immunoglobulin market is poised for strong growth from USD 22.15 billion in 2025 to USD 43.68 billion by 2034, driven by rising immunodeficiency disease prevalence, innovative product launches, and expanding manufacturing capacities. While regulatory restrictions and high therapy costs pose challenges, technological innovations and strategic partnerships continue to propel the market forward.

Segmentation By Product Type, Form, End User, and Region

By Product Type * Intravenous Immunoglobulin (IVIG)

• Primary Immunodeficiency
• Secondary Immunodeficiency
• Chronic Inflammatory Demyelinating Polyneuropathy
• Guillain-Barre Syndrome
• Immune Thrombocytopenic Purpura
• Multifocal Motor Neuropathy
• Others
• Subcutaneous Immunoglobulin (SCIG)
  • Primary Immunodeficiency
  • Secondary Immunodeficiency
  • Chronic Inflammatory Demyelinating Polyneuropathy
  • Others

By Form * Liquid

• Lyophilized

By End User * Hospitals

• Clinics
• Homecare

By Region * North America (By Product Type, Form, End User, and Country)

• U.S.
• Canada
• Europe (By Product Type, Form, End User, and Country/Sub-region)
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Product Type, Form, End User, and Country/Sub-region)
  • China
  • Japan
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America (By Product Type, Form, End User, and Country/Sub-region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Product Type, Form, End User, and Country/Sub-region)
  • GCC
  • South Africa
  • Rest of the Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Pipeline Analysis, By Key Players
• 4.2. Key Industry Developments (Mergers, Acquisitions, etc.)
• 4.3. New Product Launches, By Key Players
• 4.4. Overview of Regulatory & Reimbursement Scenario, By Key Countries/Regions
• 4.5. Prevalence of Major Diseases, By Key Countries/Regions

5. Global Immunoglobulin Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Product Type
  • 5.1.1. Intravenous Immunoglobulin (IVIG)
    • 5.1.1.1. Primary Immunodeficiency
    • 5.1.1.2. Secondary Immunodeficiency
    • 5.1.1.3. Chronic Inflammatory Demyelinating Polyneuropathy
    • 5.1.1.4. Guillain-Barre Syndrome
    • 5.1.1.5. Immune Thrombocytopenic Purpura
    • 5.1.1.6. Multifocal Motor Neuropathy
    • 5.1.1.7. Others
  • 5.1.2. Subcutaneous Immunoglobulin (SCIG)
    • 5.1.2.1. Primary Immunodeficiency
    • 5.1.2.2. Secondary Immunodeficiency
    • 5.1.2.3. Chronic Inflammatory Demyelinating Polyneuropathy
    • 5.1.2.4. Others
• 5.2. Market Analysis, Insights and Forecast - By Form
  • 5.2.1. Liquid
  • 5.2.2. Lyophilized
• 5.3. Market Analysis, Insights and Forecast - By End User
  • 5.3.1. Hospitals
  • 5.3.2. Clinics
  • 5.3.3. Homecare
• 5.4. Market Analysis, Insights and Forecast - Region
  • 5.4.1. North America
  • 5.4.2. Europe
  • 5.4.3. Asia Pacific
  • 5.4.4. Latin America
  • 5.4.5. Middle East & Africa

6. North America Immunoglobulin Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Product Type
  • 6.1.1. Intravenous Immunoglobulin (IVIG)
    • 6.1.1.1. Primary Immunodeficiency
    • 6.1.1.2. Secondary Immunodeficiency
    • 6.1.1.3. Chronic Inflammatory Demyelinating Polyneuropathy
    • 6.1.1.4. Guillain-Barre Syndrome
    • 6.1.1.5. Immune Thrombocytopenic Purpura
    • 6.1.1.6. Multifocal Motor Neuropathy
    • 6.1.1.7. Others
  • 6.1.2. Subcutaneous Immunoglobulin (SCIG)
    • 6.1.2.1. Primary Immunodeficiency
    • 6.1.2.2. Secondary Immunodeficiency
    • 6.1.2.3. Chronic Inflammatory Demyelinating Polyneuropathy
    • 6.1.2.4. Others
• 6.2. Market Analysis, Insights and Forecast - By Form
  • 6.2.1. Liquid
  • 6.2.2. Lyophilized
• 6.3. Market Analysis, Insights and Forecast - By End User
  • 6.3.1. Hospitals
  • 6.3.2. Clinics
  • 6.3.3. Homecare
• 6.4. Market Analysis, Insights and Forecast - By Country
  • 6.4.1. U.S.
  • 6.4.2. Canada

7. Europe Immunoglobulin Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Product Type
  • 7.1.1. Intravenous Immunoglobulin (IVIG)
    • 7.1.1.1. Primary Immunodeficiency
    • 7.1.1.2. Secondary Immunodeficiency
    • 7.1.1.3. Chronic Inflammatory Demyelinating Polyneuropathy
    • 7.1.1.4. Guillain-Barre Syndrome
    • 7.1.1.5. Immune Thrombocytopenic Purpura
    • 7.1.1.6. Multifocal Motor Neuropathy
    • 7.1.1.7. Others
  • 7.1.2. Subcutaneous Immunoglobulin (SCIG)
    • 7.1.2.1. Primary Immunodeficiency
    • 7.1.2.2. Secondary Immunodeficiency
    • 7.1.2.3. Chronic Inflammatory Demyelinating Polyneuropathy
    • 7.1.2.4. Others
• 7.2. Market Analysis, Insights and Forecast - By Form
  • 7.2.1. Liquid
  • 7.2.2. Lyophilized
• 7.3. Market Analysis, Insights and Forecast - By End User
  • 7.3.1. Hospitals
  • 7.3.2. Clinics
  • 7.3.3. Homecare
• 7.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 7.4.1. U.K.
  • 7.4.2. Germany
  • 7.4.3. France
  • 7.4.4. Italy
  • 7.4.5. Spain
  • 7.4.6. Scandinavia
  • 7.4.7. Rest of Europe

8. Asia Pacific Immunoglobulin Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Product Type
  • 8.1.1. Intravenous Immunoglobulin (IVIG)
    • 8.1.1.1. Primary Immunodeficiency
    • 8.1.1.2. Secondary Immunodeficiency
    • 8.1.1.3. Chronic Inflammatory Demyelinating Polyneuropathy
    • 8.1.1.4. Guillain-Barre Syndrome
    • 8.1.1.5. Immune Thrombocytopenic Purpura
    • 8.1.1.6. Multifocal Motor Neuropathy
    • 8.1.1.7. Others
  • 8.1.2. Subcutaneous Immunoglobulin (SCIG)
    • 8.1.2.1. Primary Immunodeficiency
    • 8.1.2.2. Secondary Immunodeficiency
    • 8.1.2.3. Chronic Inflammatory Demyelinating Polyneuropathy
    • 8.1.2.4. Others
• 8.2. Market Analysis, Insights and Forecast - By Form
  • 8.2.1. Liquid
  • 8.2.2. Lyophilized
• 8.3. Market Analysis, Insights and Forecast - By End User
  • 8.3.1. Hospitals
  • 8.3.2. Clinics
  • 8.3.3. Homecare
• 8.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 8.4.1. China
  • 8.4.2. Japan
  • 8.4.3. India
  • 8.4.4. Southeast Asia
  • 8.4.5. Australia
  • 8.4.6. Rest of Asia Pacific

9. Latin America Immunoglobulin Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Product Type
  • 9.1.1. Intravenous Immunoglobulin (IVIG)
    • 9.1.1.1. Primary Immunodeficiency
    • 9.1.1.2. Secondary Immunodeficiency
    • 9.1.1.3. Chronic Inflammatory Demyelinating Polyneuropathy
    • 9.1.1.4. Guillain-Barre Syndrome
    • 9.1.1.5. Immune Thrombocytopenic Purpura
    • 9.1.1.6. Multifocal Motor Neuropathy
    • 9.1.1.7. Others
  • 9.1.2. Subcutaneous Immunoglobulin (SCIG)
    • 9.1.2.1. Primary Immunodeficiency
    • 9.1.2.2. Secondary Immunodeficiency
    • 9.1.2.3. Chronic Inflammatory Demyelinating Polyneuropathy
    • 9.1.2.4. Others
• 9.2. Market Analysis, Insights and Forecast - By Form
  • 9.2.1. Liquid
  • 9.2.2. Lyophilized
• 9.3. Market Analysis, Insights and Forecast - By End User
  • 9.3.1. Hospitals
  • 9.3.2. Clinics
  • 9.3.3. Homecare
• 9.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 9.4.1. Brazil
  • 9.4.2. Mexico
  • 9.4.3. Rest of Latin America

10. Middle East & Africa Immunoglobulin Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Product Type
  • 10.1.1. Intravenous Immunoglobulin (IVIG)
    • 10.1.1.1. Primary Immunodeficiency
    • 10.1.1.2. Secondary Immunodeficiency
    • 10.1.1.3. Chronic Inflammatory Demyelinating Polyneuropathy
    • 10.1.1.4. Guillain-Barre Syndrome
    • 10.1.1.5. Immune Thrombocytopenic Purpura
    • 10.1.1.6. Multifocal Motor Neuropathy
    • 10.1.1.7. Others
  • 10.1.2. Subcutaneous Immunoglobulin (SCIG)
    • 10.1.2.1. Primary Immunodeficiency
    • 10.1.2.2. Secondary Immunodeficiency
    • 10.1.2.3. Chronic Inflammatory Demyelinating Polyneuropathy
    • 10.1.2.4. Others
• 10.2. Market Analysis, Insights and Forecast - By Form
  • 10.2.1. Liquid
  • 10.2.2. Lyophilized
• 10.3. Market Analysis, Insights and Forecast - By End User
  • 10.3.1. Hospitals
  • 10.3.2. Clinics
  • 10.3.3. Homecare
• 10.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 10.4.1. GCC
  • 10.4.2. South Africa
  • 10.4.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles (Overview, Products, SWOT Analysis, Recent Developments, Strategies, Financials (Based on Availability))
  • 11.2.1. CSL
  • 11.2.2. Takeda Pharmaceutical Company Limited
  • 11.2.3. Grifols, S.A.
  • 11.2.4. Kedrion S.p.A
  • 11.2.5. Octapharma AG
  • 11.2.6. ADMA Biologics, Inc.
  • 11.2.7. Taibang Biologic Group (China Biologic Products Holdings, Inc.)
  • 11.2.8. LFB Group
  • 11.2.9. Shanghai RAAS Blood Products Co., Ltd
  • 11.2.10. GC Biopharma Corp.